# CureDM

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/curedm

- Industry: Biotechnology
- Headquarters: Wilmington, US
- Website: www.curedm.com
- Total disclosed funding: $2.5M
- Latest round: Series B (Nov 30, 2006)
- Investors on record: 2

## About

CureDM develops innovative biopharmaceutical therapies to prevent and manage diabetes, focusing on restoring pancreatic functions through novel peptide technology.CureDM, founded in 2004 in Wilmington, US, specializes in diabetes therapies. The company has completed 3 deals, with the latest financing round on August 10, 2009, raising USD 2.10 mn. CureDM was established by individuals with a commitment to addressing diabetes-related challenges, though specific founder information is not available.CureDM, Inc. specializes in developing biopharmaceutical therapies aimed at reversing diabetes, with its core product being Human pro Islet Peptide (HIP2B). This peptide regenerates insulin-producing islets in the pancreas, promoting new islet differentiation from adult pancreatic progenitor cells. The company targets healthcare providers and pharmaceutical firms in North America, Europe, and Asia, planning distribution across urban centers and outpatient clinics.CureDM's revenue model is centered on partnerships and licensing agreements with established pharmaceutical companies. These firms handle the marketing and distribution of CureDM's proprietary peptide therapies, which generate revenue through upfront licensing fees, milestone payments for development, and royalties on product sales. Although specific pricing structures are undisclosed, revenue relies on the commercialization of HIP and associated therapies as they progress through clinical and regulatory phases.CureDM plans to leverage recent financing of USD 2.10 mn raised in August 2009 to support the launch of new peptide therapies targeting diabetes management. The company aims to expand into new geographical markets, particularly in North America and select regions in Asia, by 2025. This strategic plan includes enhancing R&D efforts to bring innovative products to market and solidifying partnerships with pharmaceutical firms to facilitate successful commercialization.

## Funding rounds

- Series B, Nov 30, 2006, $2.5M — Scientific Health Development, Calvert Research Institute

## Investors

- Scientific Health Development (https://capitalatlas.ai/funds/scientific-health-development) — Series B
- Calvert Research Institute — Series B